Research News

Breast cancer vaccine research delivers promising results

With a surprisingly simple approach in which cancer cells are first grown, ruptured and converted into nanoparticles, and then used as a vaccine, Vanderbilt researchers have developed what appears to be a promising treatment for breast cancer metastasis.

Research led by Jenna Dombroski, Ph.D. student and National Science Foundation Graduate Research Fellow in the lab of Michael King, J. Lawrence Wilson Professor of Engineering and chair of the biomedical engineering department, has found that vaccinations of tumor nano-lysate (TNL) – cancer cells broken up into thousands of nanoparticles – delay primary tumor growth and metastasis after being challenged with a tumor cell implantation. The research was published online in the journal Langmuir on June 5.

The study builds on years of King’s research on circulating tumor cells (CTC) – how cancer cells travel throughout the body in the bloodstream – and the initiation of apoptosis by the protein TNF-related apoptosis-inducing ligand (TRAIL). TRAIL, combined with fluid flow, acts as a stick of dynamite, rupturing individual cancer cells into a thousand nanoparticles.

Jenna Dombroski (Jenna Dombroski)
Michael King (Vanderbilt University)

In the lab, Dombroski and King recreated the apoptosis effect without using TRAIL at all. Instead, the duo found the precise conditions required of ultrasound forces to recreate how the protein breaks apart the cancer cells into TNL. Working in the Vanderbilt Institute of Nanoscale Science and Engineering Analytical laboratory, Dombroski and King mimicked the effect down to the exact size, shape, protein composition, and electronic charge. The TNL was then injected, and much like any other vaccine that trains the immune system to recognize and attack foreign viruses or bacteria, the injected white blood cells not only attacked the TNL but learned to clobber the CTC responsible for metastasis.

Metastasis is the latest stage of cancer, responsible for 90% of cancer-related deaths. It is caused when a cancer cell from a static tumor leaches into the bloodstream as a CTC. While most CTC die, some are able to survive in the bloodstream long enough to land in a different part of the body and grow into a new tumor in a different organ. In the U.S., breast cancer is the most diagnosed among women, with 1 in 8 facing the disease in her lifetime. It also affects men in smaller numbers. Survival rates for the localized disease are 99% but fall to 27% in the later, metastatic stage. Breast cancer has the lowest 5-year survival rate of all cancers in the U.S.

Cancer vaccine research is a rich and active field, and international research teams are working on a number of complicated processing techniques. A widely used approach consists of removing white blood cells to treat them outside the body and then reinserting them to see how they respond to cancer cells. Dombroski and King’s approach of using TNL as the vaccine has shown that the protective activity of white blood cells could be much more straightforward.

Their new technique affords the King lab ample room to optimize the vaccine by adding other chemicals to improve the efficacy of cancer immunotherapy and increase the trial size. “What I like most about this study is that it is an elegant solution to the painful problem of cancer treatment,” noted King. “We take cancer cells, hit them with ultrasound forces, deliver them as a vaccine, and it works. Next, we are going to figure out why this approach works so well, which is a lot more fun than figuring out why something isn’t working.”

This research was funded by Vanderbilt and a grant from the National Institutes of Health. Future research will be funded by Dombroski’s NSF Graduate Research Fellowship.